SCHEMBL17487569

SCHEMBL17487569

CCCc1ccc(-c2cc3ccc(CCc4cc(F)c(F)c(F)c4)cc3c(F)c2F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
ALOX5 P09917 2/20 0.36
RARB P10826 3/20 0.33
MPL P40238 5/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
BACE1 P56817 1/20 0.31
MAPT P10636 1/20 0.31
GFER P55789 1/20 0.31
PDE10A Q9Y233 1/20 0.30
RARA P10276 1/20 0.30
RARG P13631 1/20 0.30
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487648 1.00 CNR1 (0.36) CNR1CNR2ALOX5RARBMPL
SCHEMBL17487651 0.89 ALOX5 (0.34) CNR1CNR2ALOX5RARBMPL
SCHEMBL17487654 0.86 MAOB (0.43)
SCHEMBL17487801 0.83 RARB (0.41) CNR1CNR2ALOX5RARBMPL
SCHEMBL17487799 0.83 RARB (0.42) CNR1CNR2ALOX5RARBMPL
SCHEMBL17487658 0.82 S1PR1 (0.33) ALOX5GABRA1GABRB2
SCHEMBL17487566 0.81 RARB (0.34) ALOX5RARBMPLNPC1RAB9A
SCHEMBL17356686 0.81 ESR1 (0.33) RARBMPLRARARARG
SCHEMBL17487572 0.81 ESR1 (0.35) ALOX5RARBNPC1RAB9ATP53
SCHEMBL17487805 0.79 RARB (0.41) CNR1CNR2ALOX5RARBMPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD1, OCIAD2, PIEZO1 CNR1 2115/4885CNR2 3298/4885ALOX5 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.